Key Takeaways Thermo Fisher partners with AstraZeneca at BioVentureHub to drive collaborative R&D in life sciences.Thermo Fisher's new Gothenburg lab at BioVentureHub will support global pharma and biotech R&D by 2026.The AZN partnership advances drug and analytical development, reinforcing Thermo Fisher's mission globally.Thermo Fisher Scientific’s (TMO) clinical research business, PPD, announced a new research and development (R&D) partnership with AstraZeneca’s (AZN) BioVentureHub in Gothenburg, Sweden. ...

Core Insights - Illumina, Inc. (ILMN) is partnering with global pharmaceutical companies to develop companion diagnostics (CDx) based on the TruSight Oncology (TSO) Comprehensive genomic profiling test, focusing on KRAS alterations linked to cancer growth [1][10] Company Developments - The expansion of tumor-agnostic CDx claims demonstrates Illumina's commitment to enhancing patient access to precision oncology through standardized tests [2] - Illumina's TSO Comprehensive generates molecular tumor profiles to assist clinicians in matching patients with targeted therapies based on genetic mutations [3][10] - The development of CDx claims for KRAS will facilitate broader identification of patients who may benefit from targeted therapies, irrespective of tumor origin [6] Industry Context - The global CDx market was valued at $9.06 billion in 2024, with a projected compound annual growth rate of 10.5% through 2030, driven by the increasing prevalence of cancer and the demand for targeted therapies [7][8] - The integration of CDx into drug development pipelines by pharmaceutical companies is expected to enhance the success rate of novel therapeutics, further propelling market growth [8] Technological Advancements - Illumina introduced the Illumina Protein Prep, an assay that enhances next-generation sequencing (NGS)-based proteomics discovery, capable of measuring 9,500 unique human protein targets [9]